盟科药业表示，报告期内，公司营业收入同比实现小幅增长。与此同时，公司通过加强对销售、研发及 管理费用的精细化管控，优化组织架构，提升资源利用效率等措施，使得公司总体成本及费用较上年同 期有所下降。综合以上因素，公司2025年度虽仍处于亏损状态，但亏损规模较上年同期收窄。 北京商报讯（记者 丁宁）1月23日晚间，盟科药业（688373）发布2025年年度业绩预告显示，经公司财 务部门初步测算，预计2025年年度实现归属净利润约为-2.25亿元至-2.65亿元，同比亏损减少39.87%到 48.95%。 ...

（文章来源：证券日报） 证券日报网讯 1月23日，盟科药业发布2025年年度业绩预告称，公司预计2025年年度实现营业收入约为 13，500.00万元到15，500.00万元，与上年同期相比，预计增加472.72万元到2，472.72万元，同比增长 3.63%至18.98%；预计2025年年度实现归属于母公司所有者的净利润约为-26，500.00万元到-22，500.00 万元，比上年同期亏损减少17，572.12万元到21，572.12万元，同比亏损减少39.87%到48.95%。 ...

证券代码：688373 证券简称：盟科药业 公告编号：2026-014 上海盟科药业股份有限公司 2025年年度业绩预告 2025年1月1日至2025年12月31日 （二） 业绩预告情况 （1） 经上海盟科药业股份有限公司（以下简称"公司"）财务部门初步 测算，预计2025年年度实现营业收入约为13,500.00万元到15,500.00万元，与上 年同期相比，预计增加472.72万元到2,472.72万元，同比增长3.63%至18.98%。 （2） 预计2025年年度实现归属于母公司所有者的净利润约为-26,500.00万 元到-22,500.00万元，比上年同期亏损减少17,572.12万元到21,572.12万元，同比 亏损减少39.87%到48.95%。 （3） 预计2025年年度实现归属于母公司所有者扣除非经常性损益后的净 利润约为-27,400.00万元到-23,400.00万元，比上年同期亏损减少18,517.24万元到 22,517.24万元，同比亏损减少40.33%到49.04%。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完 ...

报告期内，公司营业收入同比实现小幅增长。与此同时，公司通过加强对销售、研发及管理费用的精细 化管控，优化组织架构，提升资源利用效率等措施，使得公司总体成本及费用较上年同期有所下降。综 合以上因素，公司2025年度虽仍处于亏损状态，但亏损规模较上年同期收窄。 格隆汇1月23日丨盟科药业(688373.SH)公布，公司财务部门初步测算，预计2025年年度实现营业收入约 为13,500.00万元到15,500.00万元，与上年同期相比，预计增加472.72万元到2,472.72万元，同比增长 3.63%至18.98%。 预计2025年年度实现归属于母公司所有者的净利润约为-26,500.00万元到-22,500.00万元，比上年同期亏 损减少17,572.12万元到21,572.12万元，同比亏损减少39.87%到48.95%。 预计2025年年度实现归属于母公司所有者扣除非经常性损益后的净利润约为-27,400.00万元到-23,400.00 万元，比上年同期亏损减少18,517.24万元到22,517.24万元，同比亏损减少40.33%到49.04%。 ...

Core Viewpoint - The company Mengke Pharmaceutical reported a revenue of 104 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 6.58%, attributed to a slight increase in sales volume and revenue [2] Group 1: Financial Performance - The company's revenue for the first three quarters of 2025 reached 1.04 billion yuan, marking a 6.58% increase compared to the same period last year [2] Group 2: Product Development and Clinical Trials - As of mid-2025, the drug Kantizolamine has been adopted in 580 hospitals nationwide, with 180 hospitals having formal access and bulk procurement [2] - The company initiated a Phase II clinical trial in April 2023 for oral Kantizolamine to treat complex skin and soft tissue infections in Chinese subjects aged 6 to 17, which is currently ongoing [2] - Clinical trials for other drugs, including the prodrug MRX-4, the new drug MRX-8 for resistant Gram-negative bacteria, and MRX-5 for non-tuberculous mycobacterial infections, are progressing as planned [2] - The injectable MRX-4 for treating complex skin and soft tissue infections received NDA acceptance in May 2025 [2]

（文章来源：证券日报） 证券日报网讯 1月20日，盟科药业在互动平台回答投资者提问时表示，公司暂无向欧盟成员国出口或销 售的相关业务。 ...

Core Viewpoint - The company reported a revenue growth of 6.58% year-on-year for the first three quarters of 2025, indicating a slowdown in growth rate compared to previous periods [2] Group 1: Revenue and Growth - The company's revenue for the first three quarters of 2025 reached 104 million yuan, reflecting a modest increase in sales volume and revenue compared to the same period last year [2] - The growth rate of 6.58% is significantly lower than previous growth rates, raising questions about the factors contributing to this slowdown [2] Group 2: Product Development and Clinical Trials - As of mid-2025, the company's drug, 康替唑胺片, has been adopted by 580 hospitals nationwide, with 180 hospitals achieving formal access and bulk procurement [2] - The company initiated a Phase II clinical trial in April 2023 for the oral formulation of 康替唑胺片 targeting complex skin and soft tissue infections in patients aged 6 to 17, which is currently ongoing [2] - Additional clinical trials for other drugs, including MRX-4, MRX-8, and MRX-5, are progressing, with MRX-4 receiving NDA acceptance in May 2025 for treating complex skin and soft tissue infections [2]

格隆汇1月20日丨盟科药业(688373.SH)在投资者互动平台表示，公司暂无向欧盟成员国出口或销售的相 关业务。 ...

格隆汇1月20日丨盟科药业(688373.SH)在投资者互动平台表示，公司暂无向欧盟成员国出口或销售的相 关业务。 ...

Group 1 - The "Baiyu Cong Cup" (Shanghai) 12th Excellent Public Relations Case Evaluation event concluded, with Shanghai Amcare Pharmaceutical Co., Ltd. winning two awards for its cases on tuberculosis prevention and community correction activities [1][3] - The event is a continuation of a 25-year tradition by the Shanghai Public Relations Association, now named to reflect the cultural significance of the "Baiyu Cong" from ancient Liangzhu culture, symbolizing the qualities of excellent public relations [3] - The awarded cases demonstrate Amcare Pharmaceutical's commitment to public relations, emphasizing the integration of professional expertise with social issues through effective communication and impactful actions [5][6] Group 2 - The case "Tuberculosis Prevention, A Social Responsibility" involved collaboration with authoritative institutions to create a platform for dialogue among international experts and disseminate medical knowledge through media [5] - The case "Participation in 'Three Teachers Assist One' Community Correction Activities" showcased employee volunteers engaging in community service, translating abstract concepts of responsibility into tangible social actions [6] - Amcare Pharmaceutical views public relations as a crucial support for sustainable development, aiming to enhance brand value and social impact through high-quality communication practices [6]